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1. Introduction 
Apoptosis, or programmed cell death, comes from a Greek term meaning “the falling off of 
the leaves.”  Apoptosis is also known as cell suicide and is a mechanism that is present in 
most eukaryotic cells to regulate cell numbers. It can be considered as the opposite of 
mitosis. Apoptosis is a normal part of development and is required during development, 
creation of the central nervous system, degeneration of the tadpole tail during 
metamorphosis, and the loss of certain appendages during the larval to pupal 
metamorphosis in holometabolous insects.  
Apoptosis is a major aspect of development and homeostasis. Apoptosis contributes to the 
sculpting of developing structures in vertebrate and invertebrate embryos. Deletion of 
interdigital webs in developing limbs (Hammar & Mottet, 1971), development of the fetal 
intestinal mucosa (Harmon et al., 1984), and retinal development (Penfold & Provis, 1986) all 
involve apoptosis. Apoptosis serves as a major mechanism for the regulation of cell 
numbers. For example, in the visual system of developing vertebrates, apoptosis 
preferentially eliminates neurons that form improper connections (Cowan et al., 1984). In 
the mammalian embryonic central nervous system, over 1/3 of newly formed cells die 
(Oppenheim et al., 1982) and during development of Caenorhabditis elegans 131 of the 1090 
somatic cells die (Ellis & Horvitz, 1986). Some cells seem to die because they have no 
apparent function, such as the Mullerian duct in male embryos (Price et al., 1977). Apoptosis 
can serve as a defense mechanism to remove unwanted and potentially dangerous cells, 
such as self-reactive lymphocytes (Smith et al., 1989).  
During development, the survival of lymphocytes is mediated by both active signaling and 
passive processes that regulate survival. These processes are extremely selective resulting in 
the elimination of the majority of developing lymphocytes (Owen & Jenkinson, 1992). Both 
T- and B-lymphocytes undergo developmental stages and appear to share many regulatory 
mechanisms. For example, the early survival of lymphocyte precursors is mediated 
primarily by cytokines, which both regulate the numbers of progenitors and play critical 
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roles in initiating the rearrangement of the antigen receptor genes (Baird et al., 1999). 
Developing lymphocytes must create unique antigen receptors by rearrangement to 
generate the incredible diversity characteristic of an adaptive immune response (Jung et al., 
2006). A consequence of the stochastic nature of this process is that only 1/3 of 
rearrangements are joined appropriately and give rise to a functional antigen receptor (Jung 
et al., 2006). Although several mechanisms ( use of alternative antigen receptor gene loci and 
receptor editing) exist to allow further opportunities for successful rearrangement, the 
majority of lymphocytes fail to generate functional antigen receptors and are thus 
eliminated by programmed cell death (Berg & Kang, 2001; Nemazee, 2006).  
2. Apoptosis and disease 
The suppression of apoptosis increases the susceptibility of an individual to malignancy 
whereas uncontrolled apoptosis is associated with degenerative diseases. These include 
acquired immunodeficiency syndrome (AIDS; Ameison & Capron, 1991), cancer (Ling et al., 
1993), Parkinson's disease (Walkinshaw & Waters, 1995), and Alzheimer's disease (Landfield 
et al., 1992). Abnormally elevated levels of apoptosis have been found in the lymph nodes of 
HIV-infected persons (Muro-Cacho et al., 1995). Indeed a clearer understanding of the 
regulation of apoptosis may result in better therapies.  
In this chapter, we will examine how inappropriate or excessive apoptosis can lead to 
autoimmune disorders, such as type I diabetes, autoimmune thyroid disease, rheumatoid 
arthritis, lupus and others. Furthermore, we present data demonstrating that apoptosis-
related treatments can be effective against various autoimmune disorders.  
3. Type I Diabetes 
Type I diabetes (T1D; also known as insulin-dependent or juvenile-onset diabetes) results 
from a presumed T-cell attack on the insulin-secreting β-cells of the pancreas. Controlled 
apoptotic cell death contributes to normal T-cell selection and education. Among the 
regulatory T-cells that actively suppress effector T-cells, the FOXP3+CD4+CD25high T-cells 
(Tregs) represent one of the best characterized sub-populations. There is accumulating 
evidence of a deficiency in either the frequency or function of Tregs in various human 
autoimmune diseases (Bacchetta et al., 2007), as well as in the pathogenesis of T1D (Brusko 
et al., 2005; Putnam et al., 2005). An increase in Treg apoptosis was found to correlate with a 
decline in suppressive potential of these cells. The fact that both hyperglycemic T1D subjects 
and normoglycemic at-risk subjects showed this phenomenon suggests that Treg apoptosis is 
more a precursor to, rather than a consequence of diabetes (Jailwala et al., 2009). Although 
Treg apoptosis is likely to be one of the peripheral imbalances in T1D, there is very little 
known about the pathways and genes that make Tregs sensitive to apoptosis during the 
period right after the onset of disease. Understanding the mechanism by which cytokine 
deprivation in T1D induces expression of apoptotic genes should identify potential targets 
for novel treatments. 
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Therefore, interruption of normal T-cell selection can result in the generation of autoreactive 
cells (Takuma & Faustman, 2003). However, the mechanisms by which most candidate 
genes predispose to type 1 diabetes remain unclear. A recent study reports that PTPN2, a 
candidate gene for type 1 diabetes, modulates β-cell apoptosis after exposure to type I and II 
interferons (IFNs), cytokines that contribute to β-cell loss in early type 1 diabetes (Santin et 
al., 2011). The PTPN2 gene encodes a phosphatase that is ubiquitously expressed (Doody et 
al., 2009). This phosphatase is induced by IFNγ and a synthetic dsRNA, polyinosinic-
polycitidilic acid (PIC), in β-cells and exacerbates IFNγ- and PIC-induced β-cell apoptosis by 
modulating STAT1 activation (Coli et al., 2010; Moore et al., 2009). However, the 
mechanisms connecting this candidate gene to actual β-cell death remain unclear. Inhibition 
of PTPN2 sensitizes pancreatic β-cells to apoptosis induced by both type I and II IFNs 
(Santin et al, 2011).  
4. Autoimmune Thyroid Diseases 
The Fas and TRAIL pathways are present and functional in the thyroid, and there is 
evidence suggesting their involvement in autoimmune diseases of the thyroid (Bretz et al., 
1999; Kawakami et al 2000). Giordano et al. (1997) reported the constitutive expression of 
FasL (Fas ligand) on normal and Hashimoto's thyroiditis (HT) thyrocytes using 
immunohistochemistry, flow cytometry, and RT-PCR. The percentage of FasL-positive 
thyrocytes in Graves’ thyroid was less than in normal thyroids (Sera et al., 2000). In contrast, 
another study was unable to detect FasL in thyrocytes (Xerri et al., 1997).  
Although it is widely accepted that thyrocytes express the death receptor Fas, little is known 
about how this expression is modulated. It has been demonstrated that there is increased 
expression of Fas in the thyrocytes of patients with Hashimoto’s thyroiditis (Hammond et 
al., 1997). Fas was also upregulated in the thyrocytes of patients with Graves’ disease (Sera 
et al., 2000). The thyroid gland of Graves’ disease patients contains TUNEL-positive 
thyrocytes and PCNA-positive thyrocytes, together with monocuclear cell infiltration (Sera 
et al., 2000). These data suggest that apoptosis and proliferation of thyrocytes may be 
abnormally accelerated, however, the proliferation of thyrocytes may outweigh their 
apoptosis, resulting in hyperplasia. IL-1β-treated thyrocytes become sensitive to apoptosis 
by anti-Fas IgM and activated T cells (Eguchi, 2001). Moreover, IL-1β-stimulated thyrocytes 
show reduced cytotoxic activity toward activated T cells. These results indicate that the IL-
1β produced in the thyroid gland of Graves’ disease patients might act on the thyroctyes to 
reduce their resistance to Fas-mediated apoptosis and lose their cytotoxic activity against 
activated T-cells, thus abolishing the immune-privilege status of the thyroid (Eguchi, 2001). 
This may provide an explanation for the accumulation of activated T cells in the of Graves’ 
disease patients. 
TSH receptor (TSHR) antibodies may be stimulating, blocking, or neutral in their functional 
influences and are found in patients with autoimmune thyroid disease, especially Graves’ 
disease (Morshed et al., 2010). Although neutral TSHR antibodies failed to generate cAMP 
via Gαs effectors, they initiated unique molecular signaling, possibly via recruitment of 
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multiple G proteins (Laugwitz et al., 1996; Büch et al., 2008), and thus influenced multiple 
downstream signal transduction cascades including PKC/MAPK, mTOR/S6K, NF-κB, 
certain cytokines, and oxidative stress signaling and ultimately caused rat thyroid cell 
apoptosis on chronic exposure. These findings suggest that oxidative stress may play a 
significant role in such antibody-induced thyrocyte death and thus exacerbate the chronic 
inflammatory process via antigen-driven mechanisms seen in autoimmune thyroid disease. 
Bcl-2 is mitochondiral protein that inhibits apoptosis (Park & Hockenbery, 1996). Increased 
serum Bcl-2 may be linked to accelerated apoptosis and was observed in patients with 
malignancies (Tas et al., 2006). In euthyroid Hashimoto’s thyroiditis patients compared with 
controls and euthyroid Graves’ disease, increased serum Bcl-2 has been reported (Myśliwiec 
et al., 2006). In a recent study, a tendency towards higher Bcl-2 in Hashimoto’s thyroiditis 
patients was found (Jiskra et al., 2009). Jiskra et al. (2009) further showed that there was no 
difference in serum Bcl-2 between hyperthyroid Graves’ disease and when the euthyroid 
state was achieved.  
5. Systemic Lupus Erythematosus 
A common feature of autoimmune diseases such as systemic lupus erythematosus (SLE), 
systemic sclerosis, and mixed connective tissue disease is the breakdown of tolerance of self 
antigens, a consequence of which is the production of antibodies reactive with multiple self 
proteins (von Mühlen & Tan, 1995). In patients with SLE, increased numbers of apoptotic 
lymphocytes and macrophages have been observed (Emlen et al., 1994). Other proteins have 
been implicated to play a contributing role in the pathogenesis of SLE. Protein phosphatase 
2A (PP2A) is an abundant and ubiquitously expressed, highly conserved enzyme (Janssens 
et al., 2008). It regulates a variety of cellular processes, including cell cycle progression and 
cell division, cell death, cytoskeleton dynamics, and signaling pathways (Janssens & Goris, 
2001; Sontag, 2001). PP2A is composed of a scaffold subunit (A), a catalytic subunit (C), and 
a regulatory (B) subunit. A recent study showed that the subunit Bβ is involved in the 
regulation of programmed cell death triggered by IL-2 deficiency and identified a subset of 
patients with SLE in which altered regulation of PP2A Bβ is associated with resistance to IL-
2 deprivation-induced apoptosis (Crispín et al., 2011). Apoptosis is an essential phenomenon 
that modulates the duration of immune responses and maintains the diversity of the 
lymphoid armamentarium. The importance of this process is well known, and the deficiency 
of central molecules involved in lymphocyte apoptosis causes lymphoproliferative and 
autoimmune diseases in mice and humans (Turbyville & Rao, 2010; Cohen, 2006). Apoptosis 
induced by IL-2 deprivation is triggered by intrinsic cellular signals (Lenardo et al., 1999). 
The balance between anti- and pro-apoptotic Bcl-2 family proteins determines the 
maintenance of the mitochondrial membrane potential. In the presence of IL-2, Bad is 
phosphorylated and sequestered in the cytoplasm by 14-3-3 proteins (Zha et al., 1996; 
Pastorino et al., 1999). Bim, another pro-apoptotic molecule, is absent, and levels of anti-
apoptotic Bcl-2 and Bcl-x are high. During IL-2 deprivation, Bad becomes 
dephosphorylated, dissociates from 14-3-3, and translocates to the mitochondrial membrane 
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where it binds to Bcl-2 and Bcl-x and neutralizes their anti-apoptotic capacity (Zha et al., 
1996; Yang et al., 1995). This process results in the loss of the mitochondrial membrane 
potential and leads to apoptosis. The regulation of T-cell death following activation is 
known to be altered in patients with SLE (Gergely et al., 2002; Xu et al., 2004). Recent results 
indicate that the kinetics of apoptosis following IL-2 deprivation is affected in a fraction of 
patients with SLE (Crispín et al., 2011). Importantly, induction of PP2A Bβ upon IL-2 
withdrawal was suboptimal or completely absent in these patients, which confirms the 
importance of PP2A Bβ as a molecule induced in cytokine withdrawal apoptosis and 
suggests that its faulty expression may underlie the observed phenotype. Mitochondrial 
hyperpolarization (MHP) could also contribute to the apoptosis resistance observed in SLE 
patients upon IL-2 deprivation (Gergely et al., 2002; Fernandez et al., 2006). 
6. Apoptosis in rheumatoid arthritis 
Fas and FasL both exist in membrane (mFas, mFasL) and soluble (sFas, sFasL) forms, but 
only engagement of mFas leads to the activation of caspase-8 via the Fas-associated death 
domain protein (FADD; Okamoto et al., 2000). Activated caspase-8 may lead to apoptosis 
via at least two well-described pathways: direct activation of caspase-3; and alteration of 
mitochondrial transmembrane potentials via Bcl-2 homology 3 (BH3)-interacting death-
domain agonist (BID), leading to the cytoplasmic translocation of cytochrome c, which leads 
to activation of caspase-9, which in turn activates caspase-3 (Peng, 2006). Both pathways are 
regulated at the level of caspase-8 activation by the endogenous inhibitor FADD-like IL-1β-
converting enzyme (FLICE)-inhibitory protein (FLIP), which may also be recruited by 
FADD. Interestingly, FLIP may also participate in an alternate signalling pathway, 
recruiting tumour necrosis factor-associated factor (TRAF) 1, TRAF2, the MAP kinase kinase 
kinase Raf1 and receptor-interacting protein (RIP) to activate extracellular signal-regulated 
kinase (ERK) and nuclear factor κB (NF-κB) pathways, leading to proliferation and/or 
inflammation (Peng, 2006).  
Apoptotic cells are uncommonly observed in rheumatoid arthritis (RA) tissues in vivo, but 
synoviocytes, synovial T cells and macrophages have often been observed to express high 
levels of Fas and/or FasL, and are highly susceptible to Fas/FasL-induced apoptosis in vitro. 
This contrasts with osteoarthritis, in which such abnormalities in Fas/FasL expression and 
susceptibility to Fas-induced apoptosis are generally not observed (Firestein et al., 1995; 
Nakajima et al., 1995). The discrepancy between an absence of apoptotic cells in situ and 
enhanced susceptibility to Fas-induced apoptosis in vitro probably reflects multiple anti-
apoptotic processes and/or phenomena in the rheumatoid synovium (Peng, 2006). For 
instance, increased intrasynovial and/or serum sFas appears to compete with mFas and 
prevent apoptosis of synoviocytes (Hasunuma et al., 1997). Also, in some studies, invading 
T cells have been found to be defective in FasL expression, which may account for 
ineffective clearance of activated (Fas-expressing) cells (Cantwell et al., 1997). In addition, 
synoviocyte- and/or stromal cell-derived cytokines [including transforming growth factor 
(TGF) β1 (Kawakami et al., 1996), basic fibroblast growth factor, TNF-α ,and interleukin-1 
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(Kobayashi et al., 2000a; Tsuboi et al., 1996)] protect RA synoviocytes from Fas-induced 
apoptosis, and such factors may account for the ability of RA T cells to be protected from 
apoptosis via their close interactions with fibroblast-like synoviocytes (Salmon et al., 1997). 
Furthermore, rheumatoid synovial fluid contains high levels of nitric oxide, which inhibits 
caspase-3 (Migita et al., 2001), as well as stromelysin-1 (matrix metalloproteinase-3), which 
can cleave mFasL to produce sFasL, which can compete with death-inducing mFasL 
(Matsuno et al., 2001). Thus, multiple pathways, both intra- and extracellular, impair Fas-
induced apoptosis in RA joints. Still, whether these phenomena actually underlie the disease 
etiology or simply result from the initial inflammatory pathways of RA itself remains 
undetermined. 
7. Sjogren’s Syndrome 
Sjogren’s syndrome (SS) is an autoimmune disorder that affects multiple exocrine glands, 
particular those that produce moisture to coat exposed epithelia such as the oral and ocular 
surfaces. The role of apoptosis in loss of glandular tissue in SS is less clear (Wang et al., 
2006). Environmental and genetic factors appear to contribute to the etiology of SS, although 
the evidence is relatively premature (Bolstad & Jonsson, 2002; Yamamoto, 2003). T-cell-
mediated cytotoxicity (Manganelli & Fietta, 2003; Hayashi et al., 2004) and autoantibodies 
are important in loss of gland function. There is also a failure to remove autoimmune T-cells 
at the level of thymic selection, resistance of T-cells within the gland to undergo apoptosis, 
aberrant expression of increased levels of cell adhesion molecules on glandular epithelial 
cells (facilitating infiltration of autoimmune lymphocytes to glands), up regulation of 
human leukocyte antigen (HLA)-DR, and polyclonal activation of B-lymphocytes (Rehman, 
2003). Glandular epithelial cells contribute to the autoimmune process by secreting pro-
inflammatory cytokines. Specifically, pro-inflammatory cytokines, such as tumor necrosis 
factor (TNF)-α, interleukin (IL)-1β and 6 (Roescher et al., 2010) and (Muraki et al., 2004) in 
the exocrine glands in response to immune-mediated inflammation, are found over-
expressed in the SS patients. IL-6, a potent inflammatory cytokine, is involved in acute 
phase reactions and both B and T-cell responses and the formation of germinal center-like 
structure (Roescher et al., 2010). It was found to be consistently high in saliva and serum and 
in the salivary glands of SS patients, not in subjects with xerostomia (dry mouth) only 
(Roescher et al., 2009). Furthermore, IL-1β is an effective inducer of other inflammatory 
cytokines such as IL-6, IL-8, TNF-α, and granulocyte-macrophage colony-stimulating factor 
(Fibbe et al., 1989; Chrousos, 1995). Dry-eye disease is accompanied by an increase in the 
proinflammatory forms of IL-1 (IL-1 α and mature IL-1 β) and a decrease in the biologically 
inactive precursor IL-1 β in tear fluid of SS patients (Solomon et al., 2001).  
Several studies have analyzed the role of the Fas/FasL system in salivary gland lesions of 
patients with SS. Bolstad et al. (2003) demonstrated a substantial increase in the salivary 
gland tissue expression of the negative regulator molecules PD-1 and CTLA-4 and the 
apoptotic signal molecules Fas and FasL in SS patients compared with controls, suggesting 
the involvement of the Fas/FasL system in the apoptosis of ductal and acinar epithelial cells. 
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Abu-Helu et al. (2001) showed that salivary gland epithelial cell lines (SGEC) constitutively 
expressed more membranous Fas and intracellular FasL than controls, while Shibata et al. 
(2002) detected Fas/FasL expression in ductal and acinar cells of SS patients but not in 
controls. Other studies have suggested that Fas may accelerate the apoptotic death of 
peripheral CD4 T cells in SS patients (Zeher et al., 1999; Ohashi et al., 1996). However, 
Ohlsson et al. (2001) found Fas-induced epithelial cell apoptosis to be a rare event, with a 
frequency of less than 1% in salivary glands from 18 SS patients.  
Loss of p53 activity allows the survival and proliferation of cells that should otherwise be 
eliminated. In primary SS, the expression of p53 and p21 was analyzed in salivary glands 
from 10 patients and 10 controls (Mariette et al., 2002). The p53 antigen was detected in the 
ductal cells of nine SS patients and only one control, and the p21 antigen in eight patients 
and two controls. Both antigens were located in the ductal cells of SS patients, but not in 
acinar cells. The expression of p53 and p21 in the ductal cells located around lymphoid 
infiltrates may represent a defense mechanism allowing DNA repair and thus preventing 
apoptosis, while the lack of over-expression of p53 and p21 in acinar cells could be one of 
the mechanisms responsible for acinar destruction by apoptosis in SS salivary glands.  
Kong et al. (1997) demonstrated in SS that the expression of Bcl-2 makes them resistant to 
apoptotic cell death. Nakamura et al. (2000a) showed that Bcl-2 and Bcl-x were preferentially 
expressed in infiltrating mononuclear cells rather than in the acinar and ductal epithelial 
cells from salivary glands of 17 SS patients, while Ohlsson et al. (2002) detected Bcl-2 (but 
rarely Bax) in the infiltrating lymphocytes of salivary glands from SS patients. However, 
Abu-Helu et al. (2001) found that SGEC cell lines constitutively expressed antiapoptotic 
proteins, such as Bcl-2 and cFLIP, that might protect them from both spontaneous and anti-
Fas mAb-mediated apoptosis. Kamachi et al. (2002) found an inhibitory effect of IFN-γ  in 
Bcl-2 expression, which was enhanced by coadministration of TNFα, leading to an increase 
in the apoptosis of salivary gland cells. It seems that apoptosis of the epithelial acinar and 
ductal cells may depend on the imbalance between up-regulated death-promoters (Fas and 
Bax) and down-regulated apoptosis-suppressor signals (Bcl-2). 
A stronger expression of activated caspase-3 and cleaved PARP in the acinar and ductal cells 
of salivary glands was found in 13/15 (87%) SS patients, while staining for activated caspase-
9 was negative. Nakamura et al. (2000b) analyzed the role of the X chromosome-linked 
inhibitor of apoptosis (XIAP), a member of the IAP family that inhibits the activation of 
caspases, and found a strong expression in the acinar and ductal epithelial cells of SS 
patients but not in those of controls. Because caspase-3 and caspase-7 are effector enzymes, 
XIAP might protect salivary epithelial cells from apoptotic death in SS (Nakamura et al., 
2000b). Hayashi et al. (2003) suggested that treatment with caspase inhibitors might prevent 
the development of the inflammatory process in salivary glands, and Inoue et al. (2001) 
found that caspase-inhibiting agents could inhibit the cleavage of α-fodrin. Increased 
caspase cascade activity may be involved in the progression of autoantigen proteolysis and 
tissue destruction in primary SS. The presence of activated caspase-3 in salivary glands 
indicates that excessive apoptosis may contribute to epithelial destruction in primary SS. 
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From the studies above, it can be concluded that the extrinsic apoptotic pathway as well as 
the intrinsic apoptotic pathway are involved in the pathogenesis of SS. FasL and its receptor, 
Fas, are essential in the homeostasis of the peripheral immune system. It can be considered 
that a defect in activation-induced cell death of effector T cells may result in the 
development of autoimmune exocrinopathy in Sjogren syndrome (Hayashi et al., 2004). 
Conversely, the increased rate of apoptosis of in epithelial cells in SS may result from either 
the imbalance between the down-regulated apoptosis-inhibitor Bcl-2 and the up-regulated 
apoptosis-inducer Bax, via the intrinsic pathway (Manganelli P & Fietta, 2003). 
8. Apoptosis-related therapies for autoimmune disorders 
Injection of high doses of soluble peptides leads to a state of T‑cell unresponsiveness 
(referred to as anergy) owing to a block in T‑cell proliferation and/or IL-2 production, or 
results in activation-induced cell death (AICD) after T-cell re‑stimulation with the cognate 
peptide (Burstein et al., 1992; Critchfield et al., 1994). It is thought that tolerance induced by 
soluble peptides may be useful for antigen-specific immunotherapy for the treatment of 
human autoimmune diseases. Non-obese diabetic (NOD) mice spontaneously develop type 
1 diabetes, which is characterized by T‑cell-mediated inflammation of the pancreatic islets 
(insulitis) and the eventual destruction of the insulin-producing β‑cells7. Prevention of type 
1 diabetes in NOD mice can be achieved by inducing specific T‑cell tolerance to pancreatic 
β‑cell autoantigens prior to the total destruction of all the islet β-cells (Miller et al., 2007).  
One of the more promising methods to induce tolerance for the prevention and treatment of 
autoimmune diseases, and the prevention of transplant rejection, is intravenous treatment 
with antigen-coupled, ethylene carbodiimide (ECDI)-fixed splenocytes (referred to here as 
antigen coupled cells). Treatment with antigen-coupled cells can induce anergy in vitro and 
peripheral tolerance in vivo (Miller et al., 1979; Sriram et al., 1983). The induction of tolerance 
by antigen‑coupled cell treatment has also been shown to be an effective therapy in other 
disease models, including experimental autoimmune thyroiditis (Braley-Mullen et al., 1980) 
and in the NOD mouse model of diabetes (Fife et al., 2006). Unlike soluble-peptide therapy, 
in which (depending on the disease-inducing autoantigen) the tolerizing antigen can induce 
an anaphylactic response that results in the death of treated mice, antigen-coupled-cell 
therapy does not induce an allergic response, regardless of the antigen used, and appears to 
be well tolerated at all stages of disease (Smith et al., 2005; Pedotti et al., 2001). 
Zauli et al. (2010) showed that recombinant human tumor necrosis factor (TNF)-related 
apoptosis-inducing ligand (TRAIL) ameliorated the severity of streptozotocin (STZ)-induced 
type 1 diabetes in a mouse model. Specifically, exogenous recombinant TRAIL, co-injected 
with STZ, significantly reduced the levels of islet damage with respect to animals injected 
with STZ alone (Zauli et al., 2010). Of note, treatment with recombinant TRAIL does not 
impair the viability of pancreatic islets, even when overexpressed (Dirice et al., 2009).  
Thyroid arterial embolization was shown to effectively enhance the positive expression of 
pro-apoptotic genes of Fas, FasL, Bax, Bcl-2 and P53 in Grave’s disease (GD) thyroid, thus 
 
Apoptosis and Autoimmune Disorders 107 
promoting apoptosis of GD thyroid and restoring the thyroid size and function to normal 
conditions (Zhao et al., 2009). Furthermore, T lymphocytes from GD patients treated with 
thyroid hormones accompany reduction of Bcl-2 protein expression, production of reactive 
oxygen species, and reduction of mitochondrial delta psi, resulting in apoptotic lymphocyte 
death (Mihara et al., 1999). In a study of patients with Hashimoto’s thyroiditis treated with 
Simvastatin, it was shown that CD4+ cells and B lymphocytes increased while CD8+ cells, 
natural killer cells, and activated T lymphocytes decreased significantly (Gullu et al., 2005). 
This effect is probably mediated via lymphocyte apoptosis as demonstrated with in vitro 
experiments and is not confined to Simvastatin since Mevastatin, Pravastatin and 
Cerivastatin also induced apoptosis in lymphocytes (Gullu et al., 2005). Thyroid cells can be 
sensitized to die via apoptosis by a unique combination of interferon-gamma and IL-1beta 
cytokines. Interferon-gamma/IL-1beta pretreatment sensitizes human thyroid cells to Fas-
mediated apoptosis in a complex manner that overcomes the blockade of initiator caspases 
through increased expression of cell surface Fas receptor, increases in proapoptotic 
molecules that result in mitochondrial activation, and late caspase cleavage (Mezosi et al., 
2005). 
Lupus-prone (NZB x NZW)F1 mice spontaneously develop elevated titers of anti-DNA Abs 
that contain T cell determinants in their V(H) regions. It has been shown that tolerization 
with an artificial peptide based on these T cell determinants (pConsensus (pCons)) can block 
production of anti-DNA Abs and prolong survival of the mice (Singh et al., 1995). These 
data indicate that clinical suppression of autoimmunity after administration of pCons 
depends in part on the generation of CD8+ Ti cells that suppress secretion of anti-DNA Ig 
using mechanisms that include Foxp3, TGFβ, and resistance to apoptosis (Hahn et al., 2005). 
It is postulated that in the CD8+ Ti cells, secretion of TGFβ, expression of Foxp3, and reduced 
apoptosis may likely be linked (Hahn et al., 2005). 
The above studies strongly suggest that modulation of the Fas pathway may serve as 
attractive therapeutic targets. Many current RA therapies are in fact known to induce 
apoptosis in synovial cells, such as methotrexate and TNF-directed therapies, and appear to 
do so at least in part via Fas, at least in some pathogenic cell populations, such as T cells 
and/or synovial macrophages (Oshima et al., 2000; Genestier et al., 1998; Catrina et al., 2005). 
Thus, approaches targeted more specifically against Fas/FasL may be of benefit. 
More direct evidence includes one study demonstrating the ability of anti-sense 
oligonucleotides against FLIP to sensitize RA synoviocytes strongly to Fas-induced 
apoptosis (Palao et al., 2005). Furthermore, in a model in which severe combined 
immunodeficient (scid) mice are engrafted with RA synovium, treatment with an apoptosis-
inducing anti-Fas antibody, as well as gene therapy with FasL or FADD, induces apoptosis 
in both synoviocytes and mononuclear cell populations, diminishing cellular infiltrates 
(Okamoto et al., 1998; Kobayashi et al., 2000b; Matsuno et al., 2002). Thus, if apoptotic 
strategies are to be used therapeutically in inflammatory arthritis, current evidence 
altogether strongly supports activation of the apoptotic Fas pathway as a primary objective, 
at least in RA.  
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A recent study evaluated whether cholinergic autoantibodies contained in IgG purified from 
Sjogren sera could trigger apoptosis of A253 cell line (Reina et al., 2012). The use of A253 cell 
lines has revealed that salivary gland epithelial cells are particularly susceptible to Fas-
mediated as well as Fas-independent apoptotic death after stimulation with IFN-γ, probably 
via the downregulation of the apoptosis inhibitor protein c-FLIP (Abu-Helu et al., 2001). 
Reina et al. (2012) demonstrated that anti-cholinergic autoantibodies in IgG purified from  
primary SS patient’s sera mediates apoptosis of the A253 cell line in an inositol phosphate, 
caspase-3 and metalloproteinase-3 dependent manner. 
9. Summary 
The research reviewed in this chapter clearly demonstrates that there is a delicate balance 
between death and survival signals in the pathogenesis of autoimmune disorders. The 
apoptotic pathways involved may be disease-specific or shared in common. Although the 
precise mechanisms by which apoptosis modulates autoimmune disorders in not fully 
understood, deciphering the role played by apoptosis in these disorders will lead to 
improved treatment modalities for patients. 
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